Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

被引：23
|
作者：
Girgis, Suzette [1 ,3 ]
Lin, Shun Xin Wang [1 ]
Pillarisetti, Kodandaram [1 ]
Verona, Raluca [1 ]
Vieyra, Diego [1 ]
Casneuf, Tineke [2 ]
Fink, Damien [1 ]
Miao, Xin [1 ]
Chen, Yang [1 ]
Stephenson, Tara [1 ]
Banerjee, Arnob [1 ]
Hilder, Brandi W. [1 ]
Russell, Jeffery [1 ]
Infante, Jeffrey [1 ]
Elsayed, Yusri [1 ]
Smit, Jennifer [1 ]
Goldberg, Jenna D. [1 ]
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Janssen Res & Dev LLC, Beerse, Belgium
[3] Janssen Res & Dev, 920 Route 202, Raritan, NJ 08869 USA
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 04期
关键词：
CELL MATURATION ANTIGEN; BONE-MARROW; SURVIVAL;
D O I：
10.1182/bloodadvances.2022007625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：644 / 648
页数：5
相关论文
共 50 条
  • [31] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [32] BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
    van de Donk, Niels W. C. J.
    Zweegman, Sonja
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (10) : 707 - 708
  • [33] A German Multicenter Real-World Analysis of Talquetamab in 102 Patients With Relapsed/ Refractory Multiple Myeloma
    Frenking, Jan
    Riedhammer, Christine
    Besemer, Britta
    Braune, Jan
    Brioli, Annamaria
    Brunner, Franziska
    Dampmann, Maria
    Gezer, Deniz
    Goldman-Mazur, Sarah
    Haenel, Mathias
    Hanoun, Christine
    Hoegner, Marion
    Kolditz, Katja
    Kos, Igor
    Kull, Miriam
    Leitner, Theo
    Merz, Maximilan
    von Metzler, Ivana
    Michel, Christian S.
    Teipel, Raphael
    Theurich, Sebastian
    Waesch, Ralph
    Zukovs, Romans
    Rasche, Leo
    Raab, Marc-Steffen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S52 - S53
  • [34] Increased Bone Turnover and Decreased BCMA Levels in Patients with Response to Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Ussmann, Jule
    Fischer, Luise
    Born, Patrick
    Grieb, Nora
    Hoffmann, Sandra
    Baber, Ronny
    Wang, Song-Yau
    Kloetzer, Christina
    Heyn, Simone
    Herling, Marco
    Herling, Carmen
    Jentzsch, Madlen
    Franke, Georg-Nikolaus
    Hofbauer, Lorenz
    Platzbecker, Uwe
    Vucinic, Vladan
    Weidner, Heike
    Merz, Maximilian
    BLOOD, 2023, 142
  • [35] Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy
    Le Grand, Sophie
    Karlin, Lionel
    BULLETIN DU CANCER, 2023, 110 (09) : 871 - 872
  • [36] Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma
    Tan, Carlyn Rose Co
    Derkach, Andriy
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather Jolie
    Giralt, Sergio
    Lesokhin, Alexander M.
    Korde, Neha
    Lin, Dee
    Wu, Bingcao
    Fowler, Jessica
    Fernandez, Mariana
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] BCMA x CD3 bispecific antibody treatment with teclistamab in relapsed and/or refractory multiple myeloma: a real-world monocentric analysis
    Schaefers, C.
    Thiele, B.
    Alsdorf, W.
    Kosch, R.
    Leypoldt, L.
    Bokemeyer, C.
    Weisel, K.
    Kamili, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 312 - 312
  • [38] Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM)
    Boyapati, Anita
    Richter, Joshua
    Suvannasankha, Attaya
    Lee, Hans
    Chio, Erica
    Houvras, Yariv
    Singh, Nikhil
    Liang, Tao
    Chen, Jihua
    Hazra, Anasuya
    Zhu, Yuan
    Noguera-Troise, Irene
    Lorenc, Karen Rodriguez
    Kroog, Glenn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S35 - S35
  • [39] Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients
    Chunara, Farheen
    Shah, Mansi R.
    Shah, Nishi
    Kent, Jessica
    Mohyuddin, Ghulam Rehman
    Radhakrishnan, Sabarinath, V
    Kaur, Gurbakhash
    Chakraborty, Rajshekhar
    Rasche, Leo
    Schinke, Carolina
    D'Souza, Anita
    Szabo, Aniko
    Mohan, Meera
    BLOOD, 2024, 144 : 2395 - 2395
  • [40] Treatment Outcomes of Primary vs. Referred Patients with Multiple Myeloma Receiving Talquetamab or Teclistamab
    Fries, Gina
    Alshlah, Ali
    Baran, Andrea
    Lipe, Brea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S110 - S110
12345